Stratec Valuation
Is SBSD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SBSD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SBSD (€32.6) is trading below our estimate of fair value (€62.34)
Significantly Below Fair Value: SBSD is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SBSD?
Key metric: As SBSD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
What is SBSD's PE Ratio? | |
---|---|
PE Ratio | 33.4x |
Earnings | €10.01m |
Market Cap | €334.90m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.8x |
Enterprise Value/EBITDA | 12.8x |
PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does SBSD's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 28.6x | ||
NIOX NIOX Group | 22.6x | 17.1% | UK£249.1m |
EKF EKF Diagnostics Holdings | 24x | n/a | UK£114.6m |
SN. Smith & Nephew | 35.3x | 22.5% | UK£8.6b |
TSTL Tristel | 32.3x | 17.5% | UK£209.8m |
SBSD Stratec | 33.4x | 25.4% | €334.9m |
Price-To-Earnings vs Peers: SBSD is expensive based on its Price-To-Earnings Ratio (33.4x) compared to the peer average (28.6x).
Price to Earnings Ratio vs Industry
How does SBSD's PE Ratio compare vs other companies in the European Medical Equipment Industry?
3 Companies | Price / Earnings | Estimated Growth | Market Cap |
---|---|---|---|
3 Companies | Estimated Growth | Market Cap | |
---|---|---|---|
Price-To-Earnings vs Industry: SBSD is expensive based on its Price-To-Earnings Ratio (33.4x) compared to the European Medical Equipment industry average (29.7x).
Price to Earnings Ratio vs Fair Ratio
What is SBSD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 33.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SBSD's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | €41.00 0% | 14.5% | €50.00 | €31.00 | n/a | 6 |
Nov ’25 | n/a | €41.00 0% | 14.5% | €50.00 | €31.00 | n/a | 6 |
Oct ’25 | n/a | €43.83 0% | 9.2% | €50.00 | €40.00 | n/a | 6 |
Sep ’25 | n/a | €42.33 0% | 7.0% | €47.00 | €40.00 | n/a | 6 |
Aug ’25 | n/a | €42.33 0% | 7.0% | €47.00 | €40.00 | n/a | 6 |
Jul ’25 | n/a | €42.33 0% | 7.0% | €47.00 | €40.00 | n/a | 6 |
Jun ’25 | n/a | €42.33 0% | 7.0% | €47.00 | €40.00 | n/a | 6 |
May ’25 | n/a | €43.83 0% | 12.7% | €55.00 | €40.00 | n/a | 6 |
Apr ’25 | €39.10 | €49.00 +25.3% | 14.0% | €58.00 | €40.00 | n/a | 6 |
Mar ’25 | n/a | €49.00 0% | 14.0% | €58.00 | €40.00 | n/a | 6 |
Feb ’25 | n/a | €49.00 0% | 14.0% | €58.00 | €40.00 | n/a | 6 |
Jan ’25 | n/a | €52.17 0% | 8.5% | €58.00 | €44.00 | n/a | 6 |
Dec ’24 | n/a | €54.00 0% | 4.7% | €58.00 | €50.00 | n/a | 6 |
Nov ’24 | n/a | €54.50 0% | 5.1% | €58.00 | €50.00 | n/a | 6 |
Oct ’24 | n/a | €57.00 0% | 6.2% | €62.00 | €52.00 | n/a | 6 |
Sep ’24 | n/a | €58.67 0% | 4.0% | €62.00 | €55.00 | n/a | 6 |
Aug ’24 | n/a | €59.33 0% | 4.4% | €62.00 | €55.00 | n/a | 6 |
Jul ’24 | n/a | €74.67 0% | 11.4% | €87.00 | €62.00 | n/a | 6 |
Jun ’24 | n/a | €73.67 0% | 11.0% | €87.00 | €62.00 | n/a | 6 |
May ’24 | n/a | €72.83 0% | 12.2% | €87.00 | €62.00 | n/a | 6 |
Apr ’24 | €64.30 | €75.33 +17.2% | 9.9% | €87.00 | €63.00 | €39.10 | 6 |
Mar ’24 | €76.20 | €102.00 +33.9% | 15.0% | €125.00 | €82.00 | n/a | 6 |
Feb ’24 | n/a | €102.00 0% | 15.0% | €125.00 | €82.00 | n/a | 6 |
Jan ’24 | n/a | €102.00 0% | 15.0% | €125.00 | €82.00 | n/a | 6 |
Dec ’23 | €86.30 | €102.00 +18.2% | 15.0% | €125.00 | €82.00 | n/a | 6 |
Nov ’23 | n/a | €103.83 0% | 14.0% | €125.00 | €82.00 | n/a | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Centene
US$31.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$60.74
7D
3.9%
1Y
-17.3%
Enovis
US$2.7b
Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
0I1B
US$47.21
7D
3.7%
1Y
-5.8%
Kooth
UK£59.8m
Provides digital mental health services to children, young people, and adults in the United Kingdom.
KOO
UK£1.64
7D
-2.4%
1Y
-45.0%